Table 3.

PFS for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population as of August 4, 2022)

Variable	Dostarlimab + chemotherapy (N = 121)	Pembrolizumab + chemotherapy (N = 122)
Median PFS follow-up time, months (IQR)	9.1 (6.8–11.4)	9.0 (6.7–11.2)
PFS events observed, n	64	74
Median PFS (95% CI), months	8.8 (6.7–10.4)	6.7 (4.9–7.1)
Estimated probability of PFS, % (95% CI)
6 months	61 (52–70)	52 (42–61)
9 months	46 (36–56)	36 (26–45)
Hazard ratio (95% CI)	0.70 (0.50–0.98)

PFS was assessed per RECIST v1.1 based on investigator assessment.

CI confidence interval, IQR interquartile range, ITT intention-to-treat, PFS progression-free survival, RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1.